Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | CMA1 | P23946 | 11/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545974 | 1.00 | ACE (0.58) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7538363 | 0.92 | ACE (0.59) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL22962152 | 0.92 | ACE (0.59) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7539511 | 0.92 | ACE (0.59) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL3693527 | 0.90 | ACE (0.70) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL3693522 | 0.90 | ACE (0.70) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7537159 | 0.88 | ACE (0.63) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7148899 | 0.88 | ACE (0.63) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL12658455 | 0.87 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7268512 | 0.87 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | ACE 7/4885KLK5 428/4885F2 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.